This is a real interesting merger with a biotech company patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system merging with a company that provides personal health records, both companies from California. Favrille is involved in clinical trials...
Posted to
The Medical Quack .... by Barbara Duck
on 11-10-2008
Filed under: Medically Related, Technology, healthcare, Biotech, PHR, Google Health, Cancer, clinical trials, Personal Health Records, R and D
This interview from Charlie Roses touches on many items and Nobel Prize Winner Muhammad Yunus adds what he has been able to accomplish in his part of the world in Bangladesh and how some of those principles can be applied here, coming together of both sides, different minds, different ideas that can...
Posted to
The Medical Quack .... by Barbara Duck
on 10-28-2008
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, healthcare, Biotech, Cancer, Pharmaceuticals, R and D, Economy, Banking, Milken Institute, Mahammed Yunus, Milken, Charlie Rose
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
on 10-26-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
In other words, this is called Business Intelligence. Lots of it out there to choose from and one from Microsoft specifically related to hospital management and budgets. Before the demise of Wall Street it wasn’t too long ago that I posted about the All Nighter they pulled to mine and try...
Posted to
The Medical Quack .... by Barbara Duck
on 09-26-2008
Filed under: Medically Related, Technology, Other Items of Interest, My Commentaries, Pharma, Biotech, Cancer, Business Intelligence, R and D, Wall Street, Pricing
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
on 09-05-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
You can set up a log in and donate today. Click here for details. As I had posted in a story a couple days ago, the bar has risen for venture capitalist investments, it is still there, but perhaps a little tougher to get, and with government cuts on grants and availability for research,...
Posted to
The Medical Quack .... by Barbara Duck
on 08-30-2008
Filed under: Medically Related, Other Items of Interest, My Commentaries, healthcare, Biotech, Cancer, Research, Charity, Stand up to Cancer, Donation, Entertainment, Donation Drive, Cancer Cures
Right now according to the Wall Street Journal, patients who have enjoyed an open relationship are worried that this could all change under management from Roche. Is bigger always better? Recently in the news Genentech is not happy with the offer and may hold out for more. Anyone that...